8-K: Exact Sciences Announces Preliminary Q4 2024 Results, Plans Three New Cancer Test Launches in 2025

Exact Sciences anticipates total fourth quarter revenue of $713 million and plans to launch three new cancer tests in 2025.

Summary

• Exact Sciences expects to report fourth quarter 2024 revenue of $713 million, a 10% increase compared to the same period in 2023.
• Screening revenue is expected to be $553 million, a 14% increase year-over-year, while Precision Oncology revenue is anticipated to be $161 million, a 0.4% increase.
• The company anticipates full-year 2024 revenue of $2.76 billion, a 10% increase compared to 2023, or 11% excluding COVID-19 testing.
• Full-year 2024 screening revenue is expected to be $2.104 billion, a 13% increase, and Precision Oncology revenue is expected to be $655 million, a 4% increase.
• Exact Sciences plans to launch three new cancer tests in 2025: Cologuard Plus, Oncodetect, and Cancerguard.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with strong revenue growth and plans for new product launches, but also acknowledges the preliminary nature of the results and the need for further development of new tests. The sentiment is generally optimistic but tempered by the inherent uncertainties.

Positives

• The company experienced a strong finish to 2024, positioning it for sustained growth and profitability.
• The Cologuard Plus test is expected to reduce false positives by nearly 40%, minimizing unnecessary follow-up colonoscopies.
• The Cancerguard test is being developed to detect multiple cancers in their earliest stages from a single blood draw.
• The company's Precision Oncology portfolio delivers actionable genomic insights to inform prognosis and cancer treatment.

Negatives

• Precision Oncology revenue growth was minimal in the fourth quarter, increasing only 0.4% year-over-year.

Risks

• The reported revenue figures are preliminary and unaudited, subject to change as the company completes its financial results.
• Final results for 2024 may differ materially from the preliminary estimates presented.
• The company's independent registered public accountants may identify items that could cause final reported results to be materially different from the preliminary financial estimates.
• The Cancerguard test is still in development and has not been cleared or approved by the FDA or any other regulatory authority.

Future Outlook

Exact Sciences plans to launch three new cancer tests in 2025: Cologuard Plus, Oncodetect, and Cancerguard, and expects sustained growth and profitability in the coming years.

Management Comments

• The Exact Sciences team delivered strong results to finish 2024, setting us up for sustained growth and profitability in the years to come.
• We look forward to expanding our impact as the platform supporting Cologuard and Oncotype DX powers three new cancer diagnostics launching in 2025, enabling Exact Sciences to advance cancer prevention, early detection, and personalized treatment.

Industry Context

The announcement highlights Exact Sciences' continued focus on cancer screening and diagnostics, with plans to expand its portfolio with new tests. This aligns with the broader industry trend of developing more advanced and personalized cancer detection and treatment options.

Comparison to Industry Standards

• Exact Sciences' revenue growth of 10% for the full year 2024 is a solid performance in the diagnostics industry, but the 0.4% growth in Precision Oncology revenue in Q4 2024 is below the growth rates of some competitors in the personalized medicine space, such as Guardant Health, which has seen higher growth in its liquid biopsy business.
• The planned launch of Cologuard Plus, Oncodetect, and Cancerguard in 2025 positions Exact Sciences to compete with companies like Grail and Freenome in the multi-cancer early detection market, but these tests are still in development and have not yet received regulatory approval.
• The company's Cologuard test has achieved significant market penetration with 18 million screenings since its launch, which is a strong indicator of its acceptance in the colorectal cancer screening market, but the company faces competition from traditional colonoscopy and other stool-based tests.
• The Oncotype DX test is recognized as a standard of care in breast cancer treatment, which gives Exact Sciences a competitive advantage in the precision oncology market, but the company faces competition from other genomic testing companies such as Foundation Medicine and Caris Life Sciences.

Stakeholder Impact

• Shareholders can expect continued growth and profitability, with new product launches planned for 2025.
• Employees can expect continued employment and opportunities for growth within the company.
• Customers and patients can expect access to new and improved cancer screening and diagnostic tests.
• Suppliers and creditors can expect continued business with a financially stable company.

Next Steps

• Exact Sciences plans to report full 2024 financial results during its February 2025 earnings call.
• The company will launch three new cancer tests in 2025: Cologuard Plus, Oncodetect, and Cancerguard.

Key Dates

Keywords

Exact Sciences, Cologuard, Oncotype DX, Cancerguard, Oncodetect, cancer screening, precision oncology, revenue, financial results, biomarkers